• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

20.88 +2.34 (+12.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
August 27, 2025
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
What Does the Market Think About Beam Therapeutics?
August 25, 2025
 
Via Benzinga
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
August 15, 2025
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned. 
Via Benzinga
Analyst Expectations For Beam Therapeutics's Future
February 27, 2025
 
Via Benzinga
(BEAM) - Analyzing Beam Therapeutics's Short Interest
January 31, 2025
 
Via Benzinga
Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews
January 29, 2025
 
Via Benzinga
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
June 28, 2025
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies
June 27, 2025
Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox. 
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
June 20, 2025
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
June 18, 2025
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
June 17, 2025
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab
June 11, 2025
 
Via Benzinga
10 Analysts Assess Beam Therapeutics: What You Need To Know
May 07, 2025
 
Via Benzinga
Why Beam Therapeutics Stock Tanked on Tuesday
May 06, 2025
Via The Motley Fool
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
April 21, 2025
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
April 21, 2025
 
Via Benzinga
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease
April 07, 2025
Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND 
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
April 04, 2025
 
Via Benzinga
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed'
April 04, 2025
 
Via Benzinga
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
March 28, 2025
 
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
March 28, 2025
 
Via Benzinga
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen
March 22, 2025
Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV. 
Via Benzinga
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
March 10, 2025
Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects. 
Via Benzinga
Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%
March 04, 2025
 
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies
February 22, 2025
 
Via Benzinga
Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday
February 15, 2025
Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA. 
Via Benzinga
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
February 14, 2025
 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
December 20, 2024
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
December 09, 2024
Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap